http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210046389-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbf4a72441a9802e2698cb95cf6f3949 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 |
| filingDate | 2019-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21b4534b1c718b4de0585b61c0bd003d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6ea5a1cc48dff9fa3c14afa88fff6fb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e161a25cd5fa3bf8064567988ca5df6b |
| publicationDate | 2021-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210046389-A |
| titleOfInvention | Biomarker composition for predicting drug responsiveness to platinum-based anti-cancer agents in triple negative breast cancer comprising miR-320c |
| abstract | The present invention relates to a biomarker composition for predicting drug responsiveness of patients with triple negative breast cancer to a platinum-based anticancer drug containing miR-320c as an active ingredient. We confirmed that CHEK1 expression was directly regulated by miR-320c, which was down-regulated in most TNBC cell lines. Through further studies, the present inventors have shown that the ectopic restoration of miR-320c in oxaliplatin-treated TNBC cells is through negative regulation of CHEK1, inhibiting DNA damage response, DNA repair, and improving genomic instability, and It has been found to activate death. In addition, the combination of miR-320c analogue and oxaliplatin effectively inhibited tumor progression. The above results indicate that miR-320c plays an important role in the reactivity of TNBC cells to oxaliplatin by regulating CHEK1 expression, which is a therapeutic target for increasing chemotherapy responsiveness, which will be usefully utilized in triple-negative breast cancer treatment strategies. It is expected to be able to. |
| priorityDate | 2019-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 246.